Brian Skorney

Stock Analyst at Baird

(3.84)
# 729
Out of 5,044 analysts
117
Total ratings
48.81%
Success rate
10.93%
Average return

Stocks Rated by Brian Skorney

Alto Neuroscience
Oct 20, 2025
Maintains: Outperform
Price Target: $10$16
Current: $14.04
Upside: +13.96%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58$62
Current: $42.90
Upside: +44.52%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57$52
Current: $18.11
Upside: +187.13%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30$35
Current: $23.45
Upside: +49.25%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105$121
Current: $69.95
Upside: +72.98%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46$32
Current: $23.63
Upside: +35.42%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300$255
Current: $147.86
Upside: +72.46%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652$587
Current: $652.91
Upside: -10.09%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50$55
Current: $70.46
Upside: -21.94%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95$100
Current: $118.50
Upside: -15.61%
Initiates: Outperform
Price Target: $30
Current: $16.17
Upside: +85.53%
Maintains: Outperform
Price Target: $14$5
Current: $1.22
Upside: +309.84%
Maintains: Outperform
Price Target: $26$20
Current: $10.63
Upside: +88.15%
Initiates: Outperform
Price Target: $25
Current: $4.71
Upside: +430.79%
Reiterates: Underperform
Price Target: $215
Current: $291.77
Upside: -26.31%
Maintains: Outperform
Price Target: $157$180
Current: $138.02
Upside: +30.42%
Initiates: Outperform
Price Target: $28
Current: $9.91
Upside: +182.54%
Maintains: Outperform
Price Target: $34$39
Current: $12.84
Upside: +203.74%
Initiates: Outperform
Price Target: $63
Current: $42.30
Upside: +48.94%
Maintains: Neutral
Price Target: $280$325
Current: $417.21
Upside: -22.10%
Downgrades: Neutral
Price Target: $10
Current: $21.65
Upside: -53.81%
Initiates: Outperform
Price Target: $270
Current: $3.96
Upside: +6,718.18%
Downgrades: Neutral
Price Target: $18$6
Current: $4.61
Upside: +30.15%
Maintains: Outperform
Price Target: $600$300
Current: $1.50
Upside: +19,900.00%